Published in Cancer Weekly, July 6th, 2004
This transaction will broaden Celmed's technology base, diversify its product pipeline in the oncology sector and add key shareholders from the U.S., Europe, Canada and Asia.
"This acquisition is 'step one' on the path of Celmed's aggressive growth in the field of oncology," commented Andre de Villers, president and CEO of Celmed BioSciences.
"We have spent the past year restructuring our management team, refocusing our business priorities and accelerating the clinical development of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.